AI Engines For more Details: Perplexity Kagi Labs You
Pancreatic Insufficiency: Pancreatin is commonly prescribed for individuals with pancreatic insufficiency, a condition in which the pancreas does not produce enough digestive enzymes. This can occur due to various reasons, including chronic pancreatitis, cystic fibrosis, or pancreatic surgery. Pancreatin supplementation helps compensate for the deficiency of digestive enzymes, aiding in the digestion and absorption of nutrients from food.
Improvement of Digestive Symptoms: Pancreatin supplements can alleviate symptoms associated with pancreatic insufficiency, such as abdominal pain, bloating, diarrhea, and malabsorption of nutrients. By enhancing the breakdown of carbohydrates, fats, and proteins in the small intestine, pancreatin improves digestion and reduces gastrointestinal discomfort.
Cystic Fibrosis: Individuals with cystic fibrosis often experience pancreatic insufficiency due to the thickening of mucus in the pancreas, which obstructs the flow of digestive enzymes. Pancreatin therapy is an integral part of the management of cystic fibrosis, helping improve nutrient absorption, promote weight gain, and support overall nutritional status.
Chronic Pancreatitis: In cases of chronic pancreatitis, inflammation and scarring of the pancreas can lead to impaired enzyme secretion and pancreatic insufficiency. Pancreatin supplementation may be beneficial in managing symptoms and improving digestive function in individuals with chronic pancreatitis, although its efficacy in this condition may vary among patients.
Malabsorption Syndromes: Pancreatin can be used to treat malabsorption syndromes caused by conditions other than pancreatic insufficiency, such as Crohn's disease, celiac disease, or surgical resection of the small intestine. By facilitating the digestion of nutrients, pancreatin supplements support optimal nutrient absorption and prevent nutritional deficiencies.
Easing Symptoms of Exocrine Pancreatic Cancer: Exocrine pancreatic cancer can lead to the obstruction of pancreatic ducts, impairing the secretion of digestive enzymes. Pancreatin supplementation may help alleviate symptoms associated with pancreatic cancer, such as poor appetite, weight loss, and malnutrition, by improving the digestion of food and absorption of nutrients.
Supporting Enzyme Replacement Therapy: Pancreatin is often used as part of enzyme replacement therapy (ERT), which involves the administration of exogenous digestive enzymes to individuals with pancreatic insufficiency. ERT aims to mimic the normal digestive process and improve the absorption of nutrients from food, thereby optimizing nutritional status and overall health.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium animalis | Reduces |
| species | Bifidobacterium bifidum | Reduces |
| species | Bifidobacterium breve | Reduces |
| species | Bifidobacterium catenulatum | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Bifidobacterium pseudocatenulatum | Reduces |
| species | Bifidobacterium pseudolongum | Reduces |
| species | Lactobacillus acidophilus | Increases |
| species | Lactobacillus crispatus | Increases |
| species | Lactobacillus gasseri | Increases |
| species | Lactobacillus helveticus | Increases |
| species | Lactobacillus jensenii | Increases |
| species | Lactobacillus johnsonii | Increases |
| species | Lactobacillus kefiranofaciens | Increases |
| species | Ligilactobacillus salivarius | Reduces |
| species | Limosilactobacillus reuteri | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.8 | 0.5 | 0.6 |
| ADHD | 1.8 | 0.5 | 2.6 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.5 | 0.13 |
| Allergies | 2.5 | 2.2 | 0.14 |
| Allergy to milk products | 0.5 | -0.5 | |
| Alopecia (Hair Loss) | 0.3 | -0.3 | |
| Alzheimer's disease | 2.1 | 1.1 | 0.91 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.6 | -0.2 |
| Ankylosing spondylitis | 1.3 | 1.3 | |
| Anorexia Nervosa | 0.5 | 0.5 | |
| Antiphospholipid syndrome (APS) | 0.6 | -0.6 | |
| Asthma | 1.7 | 1.9 | -0.12 |
| Atherosclerosis | 0.5 | 0.6 | -0.2 |
| Atrial fibrillation | 0.5 | 1.1 | -1.2 |
| Autism | 2.3 | 2 | 0.15 |
| Autoimmune Disease | 1.7 | 0.5 | 2.4 |
| Biofilm | 0.2 | 0.2 | |
| Brain Trauma | 1.1 | 0.5 | 1.2 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 1.2 | 1.2 | 0 |
| Carcinoma | 0.5 | 0.5 | 0 |
| Celiac Disease | 2 | 1.7 | 0.18 |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 1.1 | 0.5 | 1.2 |
| Chronic Kidney Disease | 0.8 | 0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | -0.6 | |
| Cognitive Function | 1.3 | 0.7 | 0.86 |
| Colorectal Cancer | 1.4 | 1.3 | 0.08 |
| Coronary artery disease | 0.6 | 0.6 | |
| COVID-19 | 2.4 | 1.7 | 0.41 |
| Crohn's Disease | 1.7 | 1.1 | 0.55 |
| cystic fibrosis | 0.7 | -0.7 | |
| d-lactic acidosis (one form of brain fog) | 0.5 | 2.1 | -3.2 |
| deep vein thrombosis | 0.6 | 0.6 | |
| Denture Wearers Oral Shifts | 0.6 | 0.5 | 0.2 |
| Depression | 2.8 | 3.9 | -0.39 |
| Dermatomyositis | 0.5 | -0.5 | |
| Eczema | 0.3 | 0.7 | -1.33 |
| Endometriosis | 1.4 | 0.6 | 1.33 |
| Epilepsy | 1.1 | 0.5 | 1.2 |
| erectile dysfunction | 0.5 | -0.5 | |
| Fibromyalgia | 1.1 | 1.1 | 0 |
| Functional constipation / chronic idiopathic constipation | 1.6 | 0.8 | 1 |
| gallstone disease (gsd) | 0.6 | 0.7 | -0.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0 | 0 |
| Generalized anxiety disorder | 1 | -1 | |
| Gout | 0 | 0 | |
| Graves' disease | 1.1 | 1.1 | 0 |
| Gulf War Syndrome | 0 | 0.5 | 0 |
| Hashimoto's thyroiditis | 1.3 | 0.5 | 1.6 |
| Heart Failure | 0.6 | 1.1 | -0.83 |
| High Histamine/low DAO | 1.1 | -1.1 | |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 0.6 | 0.5 | 0.2 |
| Hyperlipidemia (High Blood Fats) | 1.9 | 1.9 | |
| hypertension (High Blood Pressure | 1.1 | 2.6 | -1.36 |
| Hypothyroidism | 0.5 | -0.5 | |
| Hypoxia | 1.1 | 1.1 | 0 |
| IgA nephropathy (IgAN) | 0.6 | 0.5 | 0.2 |
| Inflammatory Bowel Disease | 1.3 | 2.1 | -0.62 |
| Insomnia | 0.2 | 0.7 | -2.5 |
| Intracranial aneurysms | 0.6 | 0.5 | 0.2 |
| Irritable Bowel Syndrome | 1.1 | 1.1 | 0 |
| ischemic stroke | 1 | 0.6 | 0.67 |
| Liver Cirrhosis | 1.9 | 1.1 | 0.73 |
| Long COVID | 1.1 | 2.4 | -1.18 |
| Mast Cell Issues / mastitis | 0.5 | -0.5 | |
| ME/CFS with IBS | 0.5 | -0.5 | |
| ME/CFS without IBS | 0.5 | -0.5 | |
| Menopause | 1.9 | 0 | 0 |
| Metabolic Syndrome | 2.5 | 2.8 | -0.12 |
| Mood Disorders | 2.2 | 3.8 | -0.73 |
| multiple chemical sensitivity [MCS] | 0.6 | -0.6 | |
| Multiple Sclerosis | 2 | 1.1 | 0.82 |
| Multiple system atrophy (MSA) | 1.2 | -1.2 | |
| neuropathic pain | 0.6 | 0.6 | |
| Neuropathy (all types) | 0.6 | -0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 2.8 | -1.33 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.5 | 1.2 |
| Obesity | 1.6 | 2.8 | -0.75 |
| obsessive-compulsive disorder | 1.2 | 1.1 | 0.09 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 0.6 | 0.9 | -0.5 |
| Parkinson's Disease | 2.5 | 1.7 | 0.47 |
| Polycystic ovary syndrome | 1.4 | 1.1 | 0.27 |
| Postural orthostatic tachycardia syndrome | 0.5 | -0.5 | |
| Premenstrual dysphoric disorder | 0.5 | 0.5 | |
| primary biliary cholangitis | 0 | 0.6 | 0 |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 0.5 | 0.6 | -0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.9 | 0.47 |
| Rosacea | 1.1 | 0.5 | 1.2 |
| Schizophrenia | 2 | 1.5 | 0.33 |
| Sjögren syndrome | 1 | -1 | |
| Sleep Apnea | 0.5 | 0.5 | |
| Slow gastric motility / Gastroparesis | 0.6 | 0.5 | 0.2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | -1.1 | |
| Stress / posttraumatic stress disorder | 0.5 | 1.1 | -1.2 |
| Systemic Lupus Erythematosus | 1.4 | 1.1 | 0.27 |
| Tic Disorder | 0.5 | -0.5 | |
| Tourette syndrome | 0.6 | 0.6 | |
| Type 1 Diabetes | 0.6 | 1.9 | -2.17 |
| Type 2 Diabetes | 2.2 | 2.1 | 0.05 |
| Ulcerative colitis | 1.9 | 2.1 | -0.11 |
| Unhealthy Ageing | 0.7 | 1.7 | -1.43 |
| Vitiligo | 0.5 | 0.5 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
